{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:38:58Z","timestamp":1787697538053,"version":"build-2784847793"},"reference-count":29,"publisher":"American Society of Hematology","issue":"4","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,25]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Clinical trial design for classical hematologic diseases is difficult because samples sizes are often small and not representative of the disease population. The American Society of Hematology initiated a roadmap project to identify barriers and make progress to integrate diversity, equity, and inclusion into trial design and conduct. Focus groups of international experts from across the clinical trial ecosystem were conducted. Eight issues identified include (1) harmonization of demographic terminology; (2) engagement of lived experience experts across the entire study timeline; (3) awareness of how implicit biases impede patient enrollment; (4) the need for institutional review boards to uphold the justice principle of clinical trial enrollment; (5) broadening of eligibility criteria; (6) decentralized trial design; (7) improving access to clinical trial information; and (8) increased community physician involvement. By addressing these issues, the hematology community can promote accessible and inclusive trials that will further inform research, clinical decision-making, and care for patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013945","type":"journal-article","created":{"date-parts":[[2024,12,9]],"date-time":"2024-12-09T16:55:16Z","timestamp":1733763316000},"page":"687-695","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["The roadmap to integrate diversity, equity, and inclusion in hematology clinical trials: an American Society of Hematology initiative"],"prefix":"10.1182","volume":"9","author":[{"given":"Alice","family":"Kuaban","sequence":"first","affiliation":[{"name":"1Scientific Affairs Department, American Society of Hematology, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9399-1012","authenticated-orcid":false,"given":"Alysha K.","family":"Croker","sequence":"additional","affiliation":[{"name":"2Health Canada, Ottawa, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Keefer","sequence":"additional","affiliation":[{"name":"3IQVIA, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7927-6418","authenticated-orcid":false,"given":"Leonard A.","family":"Valentino","sequence":"additional","affiliation":[{"name":"4National Bleeding Disorders Foundation, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6448-8170","authenticated-orcid":false,"given":"Barbara E.","family":"Bierer","sequence":"additional","affiliation":[{"name":"5Harvard Medical School, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Boateng","sequence":"additional","affiliation":[{"name":"6Sickle Cell 101, San Jose, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6208-4682","authenticated-orcid":false,"given":"Donna","family":"DiMichele","sequence":"additional","affiliation":[{"name":"7Donna DiMichele Consulting, LLC, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Fogarty","sequence":"additional","affiliation":[{"name":"8Pfizer, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Michael","family":"Gibson","sequence":"additional","affiliation":[{"name":"9Baim Institute for Clinical Research, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7213-1179","authenticated-orcid":false,"given":"Anna M.","family":"Hood","sequence":"additional","affiliation":[{"name":"10Manchester Centre for Health Psychology, Division of Psychology and Mental Health, The University of Manchester, Manchester, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloryn","family":"Hubbard","sequence":"additional","affiliation":[{"name":"11PPD, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Isgr\u00f2","sequence":"additional","affiliation":[{"name":"12AIFA Italian Medicines Agency, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Knobe","sequence":"additional","affiliation":[{"name":"13Sanofi, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Lake","sequence":"additional","affiliation":[{"name":"14Invus, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iman","family":"Martin","sequence":"additional","affiliation":[{"name":"15National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9853-1341","authenticated-orcid":false,"given":"Michel","family":"Reid","sequence":"additional","affiliation":[{"name":"16GlaxoSmithKline, Collegeville, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-9543","authenticated-orcid":false,"given":"Jonathan C.","family":"Roberts","sequence":"additional","affiliation":[{"name":"17Bleeding & Clotting Disorders Institute, Dills Family Foundation Center for Research at BCDI, Peoria, IL"},{"name":"18Departments of Pediatrics and Medicine, University of Illinois College of Medicine at Peoria, Peoria, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"11PPD, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lanre","family":"Tunji-Ajayi","sequence":"additional","affiliation":[{"name":"19Global Action Network for Sickle Cell & Other Inherited Blood Disorders, Dover, DE"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette G.C.","family":"Van Spall","sequence":"additional","affiliation":[{"name":"9Baim Institute for Clinical Research, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Voltz-Girolt","sequence":"additional","affiliation":[{"name":"20European Medicines Agency, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3967-4873","authenticated-orcid":false,"given":"Allison P.","family":"Wheeler","sequence":"additional","affiliation":[{"name":"21Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3740-0318","authenticated-orcid":false,"given":"Alan E.","family":"Mast","sequence":"additional","affiliation":[{"name":"22Thrombosis and Hemostasis Program, Versiti Blood Research Institute, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Seremetis","sequence":"additional","affiliation":[{"name":"23Novo Nordisk, Plainsboro, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"issue":"3","key":"2025032418274816100_bib1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1365-2125.2006.02617.x","article-title":"Rare diseases and orphan drugs","volume":"61","author":"Aronson","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2025032418274816100_bib2","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1002\/ajmg.a.38413","article-title":"Challenges of developing and conducting clinical trials in rare disorders","volume":"176","author":"Kempf","year":"2018","journal-title":"Am J Med Genet"},{"issue":"1","key":"2025032418274816100_bib3","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s43586-022-00100-2","article-title":"Designing clinical trials for rare diseases: unique challenges and opportunities","volume":"2","author":"Pizzamiglio","year":"2022","journal-title":"Nat Rev Methods Primers"},{"issue":"2","key":"2025032418274816100_bib4","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.2452","article-title":"Roadmap to 2030 for drug evaluation in older adults","volume":"112","author":"Liu","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025032418274816100_bib5","unstructured":"American Society of Hematology\n          . Message from the ASH president on diversity, equity, and inclusion 2020. Accessed 1 May 2024. https:\/\/www.hematology.org\/newsroom\/press-releases\/2020\/message-from-the-ash-president-on-diversity-equity-and-inclusion."},{"key":"2025032418274816100_bib6","unstructured":"U.S. Food & Drug Administration\n          . E8(R1) general considerations for clinical studies. 2022. Accessed 1 May 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/e8r1-general-considerations-clinical-studies."},{"key":"2025032418274816100_bib7","unstructured":"U.S. Food & Drug Administration\n          . Collection of race and ethnicity data in clinical trials and clinical studies for FDA-regulated medical products. 2024. Accessed 1 May 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/collection-race-and-ethnicity-data-clinical-trials-and-clinical-studies-fda-regulated-medical."},{"key":"2025032418274816100_bib8","unstructured":"Draft guidance document on the collection and analysis of disaggregated data in clinical trials: overview. 2022. Accessed 1 May 2024. https:\/\/www.canada.ca\/en\/health-canada\/programs\/consultation-proposed-agile-regulations-guidance-licensing-drugs-medical-devices\/draft-collection-analysis-disaggregated-data-clinical-trials.html."},{"key":"2025032418274816100_bib9","unstructured":"European Medicines Agency\n          . Accelerating clinical trials in the EU (ACT EU). 2022. Accessed 1 May 2024. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/clinical-trials-human-medicines\/accelerating-clinical-trials-eu-act-eu."},{"key":"2025032418274816100_bib10","unstructured":"Studies in support of special populations: geriatrics E7. 1993. Accessed 1 May 2024. https:\/\/database.ich.org\/sites\/default\/files\/E7_Guideline.pdf."},{"key":"2025032418274816100_bib11","unstructured":"Diversity plans to improve enrollment of participants from underrepresented racial and ethnic populations in clinical trials; draft guidance for industry. 2022. Accessed 1 May 2024. https:\/\/www.fda.gov\/media\/157635\/download."},{"issue":"suppl 1","key":"2025032418274816100_bib12","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/17474086.2023.2178410","article-title":"Lived experience experts: a name created by us for us","volume":"16","author":"Vazquez","year":"2023","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2025032418274816100_bib13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/tbm\/ibaa042","article-title":"Strategies of community engagement in research: definitions and classifications","volume":"11","author":"Sanders Thompson","year":"2021","journal-title":"Transl Behav Med"},{"key":"2025032418274816100_bib14","unstructured":"PCORI\n          . Ambassador Program. 2018. Accessed 1 May 2024. https:\/\/www.pcori.org\/engagement\/engage-us\/pcori-ambassador-program\/who-are-pcoris-ambassadors."},{"issue":"2","key":"2025032418274816100_bib15","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1371\/journal.pmed.0030019","article-title":"Are racial and ethnic minorities less willing to participate in health research?","volume":"3","author":"Wendler","year":"2006","journal-title":"PLoS Med"},{"key":"2025032418274816100_bib16","unstructured":"U.S. Department of Health and Human Services\n          . The Belmont report. 1979. Accessed 1 May 2024. https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/belmont-report\/read-the-belmont-report\/index.html#xbasic."},{"issue":"4","key":"2025032418274816100_bib17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/23294515.2022.2110962","article-title":"Diversity in IRB membership: views of IRB chairpersons at U.S. universities and academic medical centers","volume":"13","author":"Churchill","year":"2022","journal-title":"AJOB Empir Bioeth"},{"issue":"6535","key":"2025032418274816100_bib18","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1126\/science.abf2170","article-title":"Justice, diversity, and research ethics review","volume":"371","author":"Strauss","year":"2021","journal-title":"Science"},{"issue":"11","key":"2025032418274816100_bib19","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1001\/jama.297.11.1233","article-title":"Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review","volume":"297","author":"Van Spall","year":"2007","journal-title":"JAMA"},{"issue":"1","key":"2025032418274816100_bib20","first-page":"56","article-title":"Inclusion of special populations in clinical research: important considerations and guidelines","volume":"4","author":"Winter","year":"2018","journal-title":"J\u00a0Clin Transl Res"},{"issue":"28","key":"2025032418274816100_bib21","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1093\/eurheartj\/ehab103","article-title":"Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity","volume":"42","author":"Van Spall","year":"2021","journal-title":"Eur Heart J"},{"issue":"8","key":"2025032418274816100_bib22","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41591-023-02416-2","article-title":"Pregnant and lactating women should be included in clinical trials for cardiovascular disease","volume":"29","author":"Assadpour","year":"2023","journal-title":"Nat Med"},{"issue":"11","key":"2025032418274816100_bib23","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1093\/eurheartj\/ehac810","article-title":"Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum","volume":"44","author":"Filbey","year":"2023","journal-title":"Eur Heart J"},{"key":"2025032418274816100_bib24","unstructured":"ICH\n          . Pediatric extrapolation E11A. 2022. Accessed 1 May 2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E11A_Document_Step2_Guideline_2022_0404_0.pdf."},{"key":"2025032418274816100_bib25","unstructured":"ICH\n          . E21: inclusion of pregnant and breast-feeding individuals in clinical trials. 2023. Accessed 1 May 2024. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E21_Final_Concept_Paper_2023_1106_MCApproved.pdf."},{"issue":"9","key":"2025032418274816100_bib26","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1158\/1078-0432.CCR-20-3854","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research Prior Therapies Work Group","volume":"27","author":"Osarogiagbon","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2025032418274816100_bib27","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/cpt.2628","article-title":"Opportunities and challenges for decentralized clinical trials: European regulators' perspective","volume":"112","author":"de Jong","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"2025032418274816100_bib28","unstructured":"Decentralized Clinical Trials for Drugs\n          . Conducting clinical trials With decentralized elements. 2023. Accessed 1 May 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/decentralized-clinical-trials-drugs-biological-products-and-devices."},{"issue":"1","key":"2025032418274816100_bib29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jacc.2022.05.001","article-title":"Incorporating cultural competence and cultural humility in cardiovascular clinical trials to increase diversity among participants","volume":"80","author":"Zhu","year":"2022","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/687\/2355651\/blooda_adv-2024-013945-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/4\/687\/2355651\/blooda_adv-2024-013945-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T21:03:31Z","timestamp":1742850211000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/4\/687\/534394\/The-roadmap-to-integrate-diversity-equity-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,2,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013945","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}